A Phase 1 study of single-ascending dose intravenous administration of K1-70 to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in Japanese patients with Graves' disease
Latest Information Update: 18 Dec 2025
At a glance
- Drugs K1 70 (Primary)
- Indications Graves' disease
- Focus Adverse reactions
- Sponsors Nippon Suisan Kaisha
Most Recent Events
- 18 Dec 2025 New trial record